Acarbose is a drug that blocks alpha-glucosidase, an enzyme in the gut lining that breaks complex carbohydrates down into absorbable sugar. By slowing that breakdown, it blunts the blood-sugar spike after a meal. It has been approved for type 2 diabetes since the 1990s and is one of the few drugs, alongside rapamycin, to reliably extend lifespan in the NIH's Interventions Testing Program.
Acarbose increased median lifespan in genetically heterogeneous mice by 22% in males but only 5% in females, and increased maximum lifespan (the 90th percentile) by 11% in males and 9% in females (Harrison et al., 2014). A follow-up study tested three doses — 400, 1,000, and 2,500 ppm — and found no meaningful difference between them: the two higher doses produced 16–17% increases in male median lifespan and 4–5% in females (Harrison et al., 2019). Unlike rapamycin, acarbose does not show a clean dose-response relationship above its original tested dose — more isn't clearly better.
Acarbose has decades of use as a diabetes drug, but no dedicated human trial has tested it for lifespan or healthspan the way rapamycin's PEARL trial did. In practice, acarbose causes gas, bloating, and diarrhea for many people, since undigested carbohydrate reaching the colon gets fermented by gut bacteria — a real-world tolerability problem that limits how many people actually stay on it long enough to matter, whatever its biological effects might be.
A combination of acarbose with rapamycin has also been tested in mice, and produced lifespan benefits at least as large as either drug alone (Strong et al., 2022) — an early, promising signal for combination approaches, though this is one study and not yet an independently replicated finding.
| Study | Organism | Result | Replicated? |
|---|---|---|---|
| Harrison et al. 2014 | Mice | Median: +22% (M), +5% (F). Max: +11% (M), +9% (F) | Yes — 3 independent labs |
| Harrison et al. 2019 | Mice | +16–17% (M), +4–5% (F) at two higher doses | Confirms 2014; no added benefit from higher dose |
| Strong et al. 2022 | Mice | Acarbose + rapamycin combination extends lifespan | One study, not yet independently repeated |
Why acarbose works so much better in males than females is unresolved — the same puzzle that shows up with rapamycin, though the two drugs work through different mechanisms, which makes a single shared explanation less likely. The lack of a clean dose-response above the standard dose is also unexplained: it isn't clear whether the effect has simply plateaued, or whether a different dosing schedule would do better. And because real-world tolerability is poor, it's an open question whether any regimen exists that keeps the benefit without the gastrointestinal side effects that make people stop taking it.
Why is the effect so much stronger in male mice than female mice?
Seen consistently across studies but unexplained. The same asymmetry shows up with rapamycin, via a different mechanism, which makes a single shared cause less likely — worth testing directly rather than assuming.
Is there a dose or delivery method that keeps the benefit without the GI side effects?
Real-world tolerability is currently a bigger barrier to acarbose's use than any biological limit on its effect.
Does the acarbose plus rapamycin combination replicate?
One published result exists (Strong et al., 2022). Independent replication would matter a lot before treating this as established.
Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males
Harrison et al., Aging Cell, 2014 · Mice
Supports. The original ITP result for acarbose. Median lifespan increased 22% in males and 5% in females; maximum lifespan (90th percentile) increased 11% in males and 9% in females. Tested at three independent sites, which is what makes it trustworthy.
Acarbose improves health and lifespan in aging HET3 mice
Harrison et al., Aging Cell, 2019 · Mice
Supports. A dose-response follow-up testing 400, 1,000, and 2,500 ppm. All doses extended lifespan in both sexes, with no significant difference between doses — confirming the original finding but showing the effect plateaus rather than climbing further with dose, unlike rapamycin.
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
Strong et al., Aging Cell, 2022 · Mice
Supports. Acarbose combined with rapamycin produced lifespan benefits at least comparable to rapamycin alone. A single study — worth watching for independent replication rather than treating as settled.